MedPath

Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.

Not Applicable
Recruiting
Conditions
Cardiac Procedure Complication
Ischemic Heart Disease
Valve Heart Disease
Defect Septal
Interventions
Other: Off-pump CABG
Other: On-pump CABG
Other: Pump-assisted CABG
Other: Valve Repair Procedure without CABG.
Other: Valve Repair Procedure with CABG.
Registration Number
NCT03786965
Lead Sponsor
St. Petersburg State Pavlov Medical University
Brief Summary

The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.

Detailed Description

To assess outcomes after cardiac surgery procedures. To investigate serum level of myeloperoxidase, morphology of left atrium appendage, to perform genetic analysis and cell biology.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • ischemic heart disease with indications for operation
  • valve disease with indications for operation
  • ischemic heart disease combined with valve disease with indications for operation
Exclusion Criteria
  • patient refusal

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Off-pump CABG.Off-pump CABGOff-pump CABG.
On-pump CABG.On-pump CABGOn-pump CABG.
Pump-assisted CABG.Pump-assisted CABGPump-assisted CABG.
Heart Valve Procedure without CABG.Valve Repair Procedure without CABG.Heart Valve Procedure without CABG.
Heart Valve Procedure with CABG.Valve Repair Procedure with CABG.Heart Valve Procedure with CABG.
Primary Outcome Measures
NameTimeMethod
Stroke.within 30 days after procedure.

Stroke (MRI changes or corresponding neurologist record).

Infection or febrile.within 30 days after procedure.

Infection or febrile (t\> 37 or CRP elevation or long regeneration of surgical wound).

Respiratory dysfunction.within 30 days after procedure.

Respiratory dysfunction (pulmonary ventilation longer than 2 days).

Death within 30 days after procedure.within 30 days after procedure.

Death within 30 days after surgical procedure.

Acute myocardial infarction.within 30 days after procedure.

Acute myocardial infarction (ST-changes with troponin I \> 10 ng/ml).

Renal dysfunction.within 30 days after procedure.

Renal dysfunction if serum creatinine greater than 25% of upper reference range.

Arrhythmiawithin 30 days after procedure.

Any type of arrhythmia including AV-block.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Nikolai Bunenkov

🇷🇺

Saint-Petersburg, Non-US/Non-Canadian, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath